Exciting progress is being made in the search for better treatments for type 1 diabetes (T1D). At the recent Immunology of Diabetes Society Congress in Brisbane, Mozart Therapeutics, Inc. shared early results from a clinical trial of their new therapy, MTX-101.

MTX-101 is a new medication designed to target the immune system, which mistakenly attacks insulin-producing cells causing T1D. Instead of simply managing blood sugar levels, this therapy aims to address the underlying cause of the condition.

Because this is an early-stage clinical trial involving a small number of participants, these findings are preliminary, and more research will be needed to confirm safety and effectiveness.

In a small group of five adults with T1D taking part in this trial, researchers observed positive early signs. Participants showed an increase in protective immune cells and a decrease in the harmful ones that drive the disease. Even more promising, some individuals maintained or improved their insulin production over several months, contrasting with the decline typically seen in T1D.

While these results are still early, they suggest that MTX-101 could potentially slow or even modify the progression of type 1 diabetes, rather than just treating its symptoms. The press release is available on the Mozart Therapeutics website.

With further studies planned, including a larger global trial expected in 2027, it is hoped that this approach might lead to meaningful, long-term improvements for people living with T1D.

The trial is currently ongoing in Australia, with recruitment open in Victoria and more sites planned for Queensland. People living with type 1 diabetes who are interested in contributing to this research are encouraged to register their interest via the link below. You can find more information about this trial on our clinical trials page.